Pulmocide

Executive Summary

Pulmocide is a UK-based biopharmaceutical company focused on developing novel inhaled therapies for serious respiratory diseases. Its lead candidate, opelconazole, is a potent antifungal designed for inhalation to treat invasive pulmonary aspergillosis (IPA), a life-threatening infection in immunocompromised patients. The inhaled delivery aims to achieve high drug concentrations at the site of infection while minimizing systemic toxicity, potentially offering a significant advantage over current standard-of-care oral or intravenous azoles. Opelconazole is currently in Phase 3 clinical development, targeting a large unmet need in hematopoietic stem cell transplant recipients and other high-risk populations. If successful, opelconazole could become the first inhaled antifungal approved for IPA, addressing a market estimated to exceed $1 billion annually. The company's platform leverages expertise in pulmonary drug delivery and small molecule design, with potential to expand into other respiratory fungal infections and inflammatory diseases. Pulmocide is privately held and has been in clinical development since its founding in 2015. With Phase 3 data expected in the coming year, the company represents a compelling opportunity in the antifungal space, though regulatory and commercial risks remain. Key upcoming milestones include topline trial results, potential regulatory interactions, and partnership discussions to support late-stage development and commercialization.

Upcoming Catalysts (preview)

• TBDPhase 3 topline data for opelconazole in invasive pulmonary aspergillosis70% success
• TBDRegulatory interaction (e.g., FDA/EMA meeting) to discuss Phase 3 results and filing pathway80% success
• TBDPartnership or licensing deal for opelconazole ex-UK rights60% success